Roivant Sciences Ltd.
ROIV
株式のランク
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
株価
$33.73
最終同期: 2026-07-31
時価総額
$24.37B
変化（1日）
-2.28%
変化（1年）
90.15%
国
GB
取引 Roivant Sciences Ltd. (ROIV)
カテゴリー
Healthcare
Roivant Sciences Ltd.（ROIV）のP/S比率
October 2026 時点のP/S比率 TTM: 3.22K
Roivant Sciences Ltd. の最新の財務報告および株価によると、現在のP/S比率（TTM）は 3.22K です。2024 年末時点でのP/S比率は 65.46 でした。
Roivant Sciences Ltd. の P/S 比率の履歴（2020 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 3.22K | 1,179.79% |
| 2025 | 251.93 | 284.85% |
| 2024 | 65.46 | -23.74% |
| 2023 | 85.84 | 43.44% |
| 2022 | 59.84 | -78.74% |
| 2021 | 281.46 | 167.51% |
| 2020 | 105.21 | 0.00% |
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 10.02 | -99.69% |
US
|
|
| 40.55 | -98.74% |
US
|
|
| 3.96 | -99.88% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -99.69% |
NL
|
